Search Results
Your search for 3 matches 15327 pages
Showing 10951 - 11000Genomic Classification and Outcome in Acute Myeloid Leukemia
As reported in The New England Journal of Medicine, Elli Papaemmanuil, PhD, of the Cancer Genome Project, Wellcome Trust Sanger Institute, and colleagues have identified 11 genomic subgroups in acute myeloid leukemia (AML) associated with distinct diagnostic features and clinical outcomes. AML...
An Epic Medical Story by an Old-Style Doctor on the Front Lines of Care
The U.S. health-care system is a $3 trillion behemoth of dizzying complexity. Government oversight, ever-changing regulations, mountains of paperwork, electronic health records, initiative after initiative, and so forth, all of which has reshaped the delivery of care, for the good and bad. But...
2016-2017 Oncology Meetings
AUGUST Palliative Medicine and Supportive Oncology 2016August 3-6 • Cleveland, OhioFor more information:www.clevelandclinicmeded.com/live/courses/pallmed/default.asp 17th Annual International Lung Cancer Congress®August 4-6 • Huntington Beach, CaliforniaFor more information:...
Acupuncture: Does It Alleviate Symptoms Associated With Cancer Care?
A therapeutic modality of traditional Chinese medicine, acupuncture has been extensively investigated in Western medical settings. Its clinical use is increasingly common for the management of pain and other conditions. In the oncology setting, research demonstrates that acupuncture can...
New ASTRO Clinical Practice Statement Updates Treatment Standard for Rectal Cancer
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical practice statement, “Appropriate Customization of Radiation Therapy for Stage II and III Rectal Cancer: An ASTRO Clinical Practice Statement Using the RAND/UCLA Appropriateness Method.” An executive...
As Low-Dose CT Screening Moves Into the Clinic, Implementation Issues Move Up on the Agenda
Low-dose computed tomography (CT) screening for lung cancer in high-risk groups is moving into the clinic in the wake of its approval by the U.S. Centers for Medicaid & Medicare Services. That does not mean, however, the discussion is over. As low-dose CT moves from research to everyday...
Lung Cancer Screening: Beneficial for Certain Populations but Not Without Controversy
The National Cancer Policy Forum of the National Academies of Sciences took up the issue of lung cancer screening at its mid-June workshop. Greta Massetti, PhD, Associate Director for Science, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention (CDC), and chair of ...
ASCO Guideline on Metastatic Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Davendra P.S. Sohal, MD, MPH, of Cleveland Clinic, and colleagues, ASCO has released a clinical practice guideline on the treatment of patients with metastatic pancreatic cancer.1 Recommendations are based on an expert panel systematic review of...
ASCO Guideline on Treatment of Locally Advanced, Unresectable Pancreatic Cancer
As reported by Edward P. Balaban, DO, FASCO, of Penn State Hershey Cancer Institute, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on the treatment of locally advanced, unresectable pancreatic cancer.1 The recommendations are based on expert...
ASCO 2016 Guidelines for the Treatment of Pancreatic Cancer: Why Another Guideline?
The 5-year survival rate of those diagnosed with pancreatic cancer remains stubbornly fixed around 5%. Even in the 20% of cases in which surgical resection is undertaken for curative intent, the 5-year survival rate after surgery is 20% to 30%. As we make progress in other cancers with decreasing...
Pap Smear Screenings May Help Prevent Cervical Cancer in Women Over 65
A new study from the University of Illinois confirms a link between Papanicolaou (Pap) smear screenings and a lower risk of developing cervical cancer in women over age 65. However, most American health guidelines discourage women in that age range from receiving screenings unless they have...
ASCO Guideline on Potentially Curable Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Alok A. Khorana, MD, of Cleveland Clinic, and colleagues, ASCO has released a clinical practice guideline on the treatment of potentially curable pancreatic cancer.1 The recommendations are based on an expert panel systematic review of the...
ASCO Guideline on Endocrine Therapy for Hormone Receptor–Positive Metastatic Breast Cancer
As reported by Hope S. Rugo, MD, of the University of California San Francisco Comprehensive Cancer Center, and colleagues in the Journal of Clinical Oncology, ASCO has released a clinical practice guideline on endocrine therapy for hormone receptor–positive metastatic breast cancer.1 The...
Five-Year Survival Data: Brentuximab Vedotin May Be Curative in Some Patients With Hodgkin Lymphoma
Five-year survival data published by Chen et al in Blood suggest that the targeted therapy brentuximab vedotin (Adcetris) may be curative in some patients with Hodgkin lymphoma whose disease has persisted despite receiving previous therapies. This multinational phase II study examined brentuximab...
Road to Successful Use of Real-World Evidence for Drug Development Is Long and Rocky
Friends of Cancer Research (Friends) has been a leader in the push for better and faster cancer drug development. Now it is tackling the use of real-world evidence in clinical trials. This is the report of a meeting on the subject that took place on June 16 in Washington, DC.1 Real-world evidence...
ASCO and MECC Sponsor International Palliative Care Workshop in Kazakhstan
ASCO recently collaborated with the Middle East Cancer Consortium (MECC) to provide a 3-day International Palliative Care Workshop in Kazakhstan for health-care professionals, advocates, and volunteers in the former capital of Almaty. Dilyara Kaidarova, MD, PhD, Director of the Almaty Oncology...
Quick Takes on Promising New Approaches to Treating Breast Cancer
At the 2016 ASCO Annual Meeting, researchers reported encouraging results for several new drugs and treatment strategies for breast cancer. The ASCO Post brings you brief summaries of a select few. Abemaciclib Trial The cyclin-dependent kinase 4/6 (CDK4/6) inhibitor abemaciclib produced responses...
American Cancer Society Endorses HPV Vaccine Recommendations From CDC ACIP
The American Cancer Society (ACS) has endorsed human papillomavirus (HPV) vaccination recommendations from the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), the principal source of guidance on U.S. immunization policy. The ACS's...
Selected Hematology Abstracts From the 2016 ASCO Annual Meeting
Here are several abstracts selected from the proceedings of the 2016 ASCO Annual Meeting, focusing on clinical trials on therapeutics in different types of leukemia, multiple myeloma, follicular lymphoma, and central nervous system (CNS) lymphoma. For full details of these study abstracts, visit...
App Triggers Earlier Detection of Relapse, May Help Improve Survival of Patients With Lung Cancer
Web-based applications have invaded mainstream culture and grabbed the attention of multitudes of people around the world. According to a study presented at the 2016 ASCO Annual Meeting, an app may also contribute to extending the lives of people with cancer and, at the same time, reduce...
PHEREXA: Benefit for Second-Line Pertuzumab Questionable
In the second-line metastatic breast cancer setting, the addition of pertuzumab (Perjeta) to trastuzumab (Herceptin)/capecitabine did not significantly improve progression-free survival, results of the phase III PHEREXA trial showed.1 This is the first randomized trial to evaluate the efficacy of ...
Studies Suggest Bright Future for Combination Immunotherapy in Advanced Melanoma, but Questions Remain
Two studies presented at the 2016 ASCO Annual Meeting focused on the use of combination immunotherapy in the treatment of patients with advanced melanoma. Updated results from the phase III CheckMate 067 trial centered on the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) compared...
CMS Proposal for Part B Drug Payment: A Poorly Conceived Experiment
On March 11, 2016, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule in the Federal Register to test a change in reimbursement for Part B drugs.1 The first phase involves changing the 6% add-on to the average sales price (ASP) used to make drug payments under Part B to...
CNS-IPI for CNS Relapse in Diffuse Large B-Cell Lymphoma
As reported in the Journal of Clinical Oncology, Schmitz et al have developed and validated a risk score for CNS relapse—the Central Nervous System International Prognostic Index (CNS-IPI)—in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab [Rituxan]...
Charting a New Course at the FDA
In February, after serving for a year as the U.S. Food and Drug Administration’s (FDA’s) Deputy Commissioner for Medical Products and Tobacco, Robert M. Califf, MD, MACC, was named the agency’s Commissioner of Food and Drugs. Prior to his appointment at the FDA, Dr. Califf was the Donald F....
No Survival Benefit for Cabozantinib Reported in Previously Treated Metastatic Castration-Resistant Prostate Cancer
Smith et al found no improvement in overall survival with cabozantinib (Cometriq) vs prednisone in patients with previously treated metastatic castration-resistant prostate cancer, in the phase III COMET-1 trial reported in the Journal of Clinical Oncology. Cabozantinib, which inhibits MET, VEGF...
Swiss Study Examines Cost-Effectiveness of Nivolumab vs Docetaxel in Advanced Nonsquamous NSCLC
Nivolumab, a checkpoint inhibitor approved for patients with squamous and nonsquamous non–small cell lung cancer (NSCLC) in 2015, is not cost-effective when compared to treatment with docetaxel, chemotherapy medication. However, a Swiss analysis showed the cost-effectiveness of nivolumab is...
Analysis Indicates Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage DLBCL
In an analysis of data from SWOG studies reported in the Journal of Clinical Oncology, Stephens et al found as continued risk of relapse among patients with limited-stage diffuse large B-cell lymphoma (DLBCL) irrespective of whether they received CHOP (cyclophosphamide, doxorubicin, vincristine,...
Early Results Find Pembrolizumab Active in Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Findings in a classical Hodgkin lymphoma cohort in the phase Ib KEYNOTE-013 trial, reported by Armand et al in the Journal of Clinical Oncology, indicate that pembrolizumab (Keytruda) is active in patients with disease progressing on or after brentuximab vedotin (Adcetris) treatment. Study Details ...
PET/MRI: A One-Stop Imaging Test to Detect Prostate Cancer?
A University of Michigan study published by Piert et al in The Journal of Nuclear Medicine reported that the addition of molecular imaging based on F-18-choline positron-emission tomography (PET) improves the identification of significant prostate cancer over multiparametric prostate magnetic...
Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial After FDA Clinical Hold
Juno Therapeutics, Inc, announced on July 12, 2016, that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the phase II clinical trial of JCAR015 (known as the ROCKET trial) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Under the ...
Opportunistic Salpingectomy for Ovarian Cancer Prevention Adopted Without Adverse Surgical Outcomes
A surgical procedure recommended to reduce the future risk of ovarian cancer has been successfully implemented throughout Kaiser Permanente in Northern California without a change in surgical outcomes, according to research published by Garcia et al in Obstetrics & Gynecology. Previous...
Long-Term Benefit of Lenalidomide/Dexamethasone Reported in High-Risk Smoldering Multiple Myeloma
As reported by Mateos et al in The Lancet Oncology, long-term follow-up in the phase III QuiRedex trial indicates continued benefit of lenalidomide (Revlimid)/dexamethasone vs observation in preventing disease progression in patients with high-risk smoldering multiple myeloma. Study Details In...
First-Line Nivolumab Monotherapy Active in Advanced NSCLC
As part of the phase I CheckMate 012 study reported by Gettinger et al in the Journal of Clinical Oncology, nivolumab (Opdivo) monotherapy was found to be active as first-line treatment in advanced non–small cell lung cancer (NSCLC). The study is also examining first-line nivolumab plus...
First-Line Nivolumab Active in Combination With Platinum-Based Doublets in Advanced NSCLC
Nivolumab (Opdivo) was found to be active combined with platinum-based doublets as first-line treatment of advanced non–small cell lung cancer (NSCLC), as part of the phase I CheckMate 012 study reported by Rizvi et al in the Journal of Clinical Oncology. The study is also evaluating...
World GI 2016: Chemoradiotherapy After Surgery for Gastric Cancer Shows Similar Outcomes to Postoperative Chemotherapy
Postoperative treatment intensification with chemoradiotherapy does not achieve better outcomes compared to postoperative chemotherapy in patients with gastric cancer who have already undergone preoperative chemotherapy, according to phase III data presented by Verheij et al at the ESMO 18th World...
World GI 2016: Phase III RESORCE Study Data Show Regorafenib Improves Overall Survival in Previously Treated Patients With Unresectable Liver Cancer
Results from the phase III RESORCE trial show that regorafenib (Stivarga) tablets achieved a median overall survival improvement in patients with unresectable hepatocellular carcinoma (HCC) that progressed after treatment with sorafenib (Nexavar) tablets. The study, presented by Bruix et al during...
Updated Outcomes and Impact of Age in FIRST Trial in Multiple Myeloma
As reported by Hulin et al in the Journal of Clinical Oncology, the updated findings in the phase III FIRST trial continue to show improved progression-free and overall survival with continuous lenalidomide (Revlimid) plus low-dose dexamethasone (Rd) vs melphalan, prednisone, and thalidomide (MPT)...
Study Finds Incidence of Mutations in DNA-Repair Genes Significantly Higher in Men With Metastatic Prostate Cancer
The incidence of mutations in DNA-repair genes was significantly higher among men with metastatic prostate cancer than among men with localized disease (11.8% vs 4.6%), according to a study by Pritchard et al reported in The New England Journal of Medicine. In addition, the frequency ...
Mixed Results With Hypofractionated vs Conventional Radiotherapy for Localized Prostate Cancer
Investigators of two European phase III trials have reached different conclusions on whether hypofractionated radiotherapy should replace conventional radiotherapy as a new standard of treatment in localized prostate cancer. The CHHiP trial findings favoring hypofractionation were reported by David ...
Ann G. Schwartz, PhD, MPH, Elected to ILCCO Steering Committee
Ann G. Schwartz, PhD, MPH, Deputy Center Director and Executive Vice President for Research and Academic Affairs at the Barbara Ann Karmanos Cancer Institute and Professor and Associate Chair in the Department of Oncology at Wayne State University School of Medicine, was recently elected to a...
Erika P. Hamilton, MD, Named Director of Breast and Gynecologic Cancer Research
Sarah Cannon has announced the promotion of Erika P. Hamilton, MD, to Director of the institution’s Breast and Gynecologic Cancer Research Program. Over the past 3 years, Dr. Hamilton has been instrumental in the growth and success of the program. “Erika has quickly become a recognized thought...
2016 Oncology Meetings
JULY Pan Pacific Lymphoma ConferenceJuly 18-22 • Koloa, Hawaii For more information: www.unmc.edu/cce/catalog/clinicmed/panpacificlymphoma/index.html UK Breast Cancer Research SymposiumJuly 22-23 London, United Kingdom For more information: http://breastcancerconference.org Mayo Clinic Oncology...
Prevention Needed to Stem Global Rise in Human Papillomavirus–Related Anal Cancer
The incidence rate of human papillomavirus (HPV)-related anal cancer and its precursor lesion, anal intraepithelial neoplasia, is rising in the United States and globally. Although 5-year survival rates in localized disease are generally favorable, survival in metastatic disease remains poor,...
A Concerned Physician Reflects on Today’s Doctor-Patient Relationship
Doctoring isn’t what it used to be. Like many other professions, it has gone through a multitude of changes ostensibly to improve efficiencies and lower costs. The digital age has reshaped clinical practice from the front office to the exam room. And with the advent of electronic health records...
Managing Upper Extremity Dysfunction in Breast Cancer Survivors
With an increased number of breast cancer survivors and patients with metastatic disease living longer, it is imperative for oncology care providers to manage issues of new and chronic upper extremity dysfunction as a result of the malignancy itself or its treatment. As one of my patients...
Greatest Benefit of Adjuvant Exemestane in Premenopausal Women at Higher Risk of Breast Cancer Recurrence
In an analysis of the SOFT and TEXT trials reported in the Journal of Clinical Oncology, Meredith M. Regan, ScD, of Dana-Farber Cancer Institute, and colleagues found that the greatest benefit of adjuvant exemestane in reducing breast cancer recurrence was among women with the greatest risk of...
Complexities in the Diagnosis and Management of Amyloidosis
Question 1: What is the next best step for this patient? Correct Answer: C. Determination of amyloid subtype. Expert Perspective Amyloidosis encompasses a heterogeneous group of diseases bound by the characteristic deposition of amyloid fibrils in soft tissues and bone marrow, and it could be...
Complexities in the Diagnosis and Management of Amyloidosis
Case Study A 70-year-old man is referred to your clinic for a consultation. Recently, a diagnosis of IgG monoclonal gammopathy of undetermined significance (MGUS) was established. Medical history is significant for essential hypertension, type II diabetes mellitus, hyperlipidemia, and atrial...
Routine Prophylactic vs Deferred Radiotherapy for Procedure-Tract Metastases in Malignant Pleural Mesothelioma
Prophylactic radiotherapy after surgery and large-bore pleural procedures did not result in significant reduction in the incidence of procedure-tract metastases in malignant pleural mesothelioma, according to the UK phase III SMART trial reported by Clive et al in The Lancet Oncology. Study...
